241 related articles for article (PubMed ID: 27981848)
1. Striking the Optimal Solubility-Permeability Balance in Oral Formulation Development for Lipophilic Drugs: Maximizing Carbamazepine Blood Levels.
Beig A; Miller JM; Lindley D; Dahan A
Mol Pharm; 2017 Jan; 14(1):319-327. PubMed ID: 27981848
[TBL] [Abstract][Full Text] [Related]
2. Methacrylate-Copolymer Eudragit EPO as a Solubility-Enabling Excipient for Anionic Drugs: Investigation of Drug Solubility, Intestinal Permeability, and Their Interplay.
Fine-Shamir N; Dahan A
Mol Pharm; 2019 Jul; 16(7):2884-2891. PubMed ID: 31120762
[TBL] [Abstract][Full Text] [Related]
3. The solubility, permeability and the dose as key factors in formulation development for oral lipophilic drugs: Maximizing the bioavailability of carbamazepine with a cosolvent-based formulation.
Fine-Shamir N; Beig A; Miller JM; Dahan A
Int J Pharm; 2020 May; 582():119307. PubMed ID: 32276090
[TBL] [Abstract][Full Text] [Related]
4. Toward Successful Cyclodextrin Based Solubility-Enabling Formulations for Oral Delivery of Lipophilic Drugs: Solubility-Permeability Trade-Off, Biorelevant Dissolution, and the Unstirred Water Layer.
Fine-Shamir N; Beig A; Zur M; Lindley D; Miller JM; Dahan A
Mol Pharm; 2017 Jun; 14(6):2138-2146. PubMed ID: 28505451
[TBL] [Abstract][Full Text] [Related]
5. Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption.
Beig A; Miller JM; Dahan A
Eur J Pharm Biopharm; 2012 Jun; 81(2):386-91. PubMed ID: 22387337
[TBL] [Abstract][Full Text] [Related]
6. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations.
Miller JM; Beig A; Carr RA; Webster GK; Dahan A
Mol Pharm; 2012 Mar; 9(3):581-90. PubMed ID: 22280478
[TBL] [Abstract][Full Text] [Related]
7. Head-To-Head Comparison of Different Solubility-Enabling Formulations of Etoposide and Their Consequent Solubility-Permeability Interplay.
Beig A; Miller JM; Lindley D; Carr RA; Zocharski P; Agbaria R; Dahan A
J Pharm Sci; 2015 Sep; 104(9):2941-7. PubMed ID: 25989509
[TBL] [Abstract][Full Text] [Related]
8. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
Miller JM; Beig A; Carr RA; Spence JK; Dahan A
Mol Pharm; 2012 Jul; 9(7):2009-16. PubMed ID: 22632106
[TBL] [Abstract][Full Text] [Related]
9. Ethanol-based solubility-enabling oral drug formulation development: Accounting for the solubility-permeability interplay.
Fine-Shamir N; Dahan A
Int J Pharm; 2024 Mar; 653():123893. PubMed ID: 38346600
[TBL] [Abstract][Full Text] [Related]
10. Active intestinal drug absorption and the solubility-permeability interplay.
Porat D; Dahan A
Int J Pharm; 2018 Feb; 537(1-2):84-93. PubMed ID: 29102702
[TBL] [Abstract][Full Text] [Related]
11. Adequate formulation approach for oral chemotherapy: Etoposide solubility, permeability, and overall bioavailability from cosolvent- vs. vitamin E TPGS-based delivery systems.
Fine-Shamir N; Beig A; Dahan A
Int J Pharm; 2021 Mar; 597():120295. PubMed ID: 33497706
[TBL] [Abstract][Full Text] [Related]
12. Hydrotropic Solubilization of Lipophilic Drugs for Oral Delivery: The Effects of Urea and Nicotinamide on Carbamazepine Solubility-Permeability Interplay.
Beig A; Lindley D; Miller JM; Agbaria R; Dahan A
Front Pharmacol; 2016; 7():379. PubMed ID: 27826241
[TBL] [Abstract][Full Text] [Related]
13. Solubility-enabling formulations for oral delivery of lipophilic drugs: considering the solubility-permeability interplay for accelerated formulation development.
Fine-Shamir N; Dahan A
Expert Opin Drug Deliv; 2024; 21(1):13-29. PubMed ID: 38124383
[TBL] [Abstract][Full Text] [Related]
14. Identification of suitable formulations for high dose oral studies in rats using in vitro solubility measurements, the maximum absorbable dose model, and historical data sets.
Wuelfing WP; Kwong E; Higgins J
Mol Pharm; 2012 May; 9(5):1163-74. PubMed ID: 22394323
[TBL] [Abstract][Full Text] [Related]
15. The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs.
Dahan A; Miller JM
AAPS J; 2012 Jun; 14(2):244-51. PubMed ID: 22391790
[TBL] [Abstract][Full Text] [Related]
16. A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling.
Gao Y; Carr RA; Spence JK; Wang WW; Turner TM; Lipari JM; Miller JM
Mol Pharm; 2010 Oct; 7(5):1516-26. PubMed ID: 20715778
[TBL] [Abstract][Full Text] [Related]
17. Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations.
Beig A; Agbaria R; Dahan A
PLoS One; 2013; 8(7):e68237. PubMed ID: 23874557
[TBL] [Abstract][Full Text] [Related]
18. The solubility-permeability interplay and oral drug formulation design: Two heads are better than one.
Dahan A; Beig A; Lindley D; Miller JM
Adv Drug Deliv Rev; 2016 Jun; 101():99-107. PubMed ID: 27129443
[TBL] [Abstract][Full Text] [Related]
19. Advantage of the Dissolution/Permeation System for Estimating Oral Absorption of Drug Candidates in the Drug Discovery Stage.
Miyaji Y; Fujii Y; Takeyama S; Kawai Y; Kataoka M; Takahashi M; Yamashita S
Mol Pharm; 2016 May; 13(5):1564-74. PubMed ID: 27031624
[TBL] [Abstract][Full Text] [Related]
20. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
Buckley ST; Frank KJ; Fricker G; Brandl M
Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
